Bank of New York Mellon Corp Cuts Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Bank of New York Mellon Corp decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,392 shares of the biotechnology company's stock after selling 6,826 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.16% of Ascendis Pharma A/S worth $13,546,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S during the third quarter worth about $30,000. Blue Trust Inc. lifted its position in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 328 shares during the period. GAMMA Investing LLC lifted its position in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 214 shares during the period. Sanctuary Advisors LLC purchased a new stake in Ascendis Pharma A/S during the fourth quarter valued at approximately $203,000. Finally, Legato Capital Management LLC increased its holdings in Ascendis Pharma A/S by 7.5% during the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after buying an additional 134 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock traded up $0.67 during trading hours on Friday, hitting $152.98. The company's stock had a trading volume of 405,736 shares, compared to its average volume of 456,317. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $158.00. The firm has a fifty day moving average of $138.31 and a 200-day moving average of $134.71. The stock has a market cap of $9.28 billion, a price-to-earnings ratio of -21.55 and a beta of 0.62.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ASND has been the subject of a number of analyst reports. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Finally, Cantor Fitzgerald raised their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $202.36.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.